Trial Profile

A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARCT-032 (Primary)
Indications Cystic fibrosis
Focus Adverse reactions
Acronyms LunairCF
Sponsors Arcturus Therapeutics

Most Recent Events

06 Mar 2025 According to Arcturus Therapeutics media release, the Company expects to provide interim data from participants who completed dosing in the ARCT-032 Phase 2 study by the end of Q2 2025.
06 Jan 2025 According to Arcturus Therapeutics media release, the first CF participants initiated dosing in December 2024
24 Dec 2024 Status changed to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com